These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18188762)

  • 1. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial.
    Wagena EJ; de Vos A; Horwith G; van Schayck CP
    Nicotine Tob Res; 2008 Jan; 10(1):213-8. PubMed ID: 18188762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.
    Hatsukami DK; Rennard S; Jorenby D; Fiore M; Koopmeiners J; de Vos A; Horwith G; Pentel PR
    Clin Pharmacol Ther; 2005 Nov; 78(5):456-67. PubMed ID: 16321612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
    Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
    Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity.
    Maurer P; Jennings GT; Willers J; Rohner F; Lindman Y; Roubicek K; Renner WA; Müller P; Bachmann MF
    Eur J Immunol; 2005 Jul; 35(7):2031-40. PubMed ID: 15971275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
    Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
    Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Shiffman S
    Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation.
    Becker KM; Rose JE; Albino AP
    Nicotine Tob Res; 2008 Jul; 10(7):1139-48. PubMed ID: 18629723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients.
    Fattom A; Fuller S; Propst M; Winston S; Muenz L; He D; Naso R; Horwith G
    Vaccine; 2004 Dec; 23(5):656-63. PubMed ID: 15542186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
    Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
    Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study.
    Marsh HS; Dresler CM; Choi JH; Targett DA; Gamble ML; Strahs KR
    Clin Ther; 2005 Oct; 27(10):1571-87. PubMed ID: 16330293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
    Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
    Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niccine®, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial.
    Tonstad S; Heggen E; Giljam H; Lagerbäck PÅ; Tønnesen P; Wikingsson LD; Lindblom N; de Villiers S; Svensson TH; Fagerström KO
    Nicotine Tob Res; 2013 Sep; 15(9):1492-501. PubMed ID: 23471101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between adherence to daily nicotine patch use and treatment efficacy: secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers.
    Shiffman S; Sweeney CT; Ferguson SG; Sembower MA; Gitchell JG
    Clin Ther; 2008 Oct; 30(10):1852-8. PubMed ID: 19014840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of subcutaneous or intramuscular administration of a monovalent inactivated vaccine against Leptospira interrogans serogroup Icterohaemorrhagiae in healthy volunteers.
    Laurichesse H; Gourdon F; Smits HL; Abdoe TH; Estavoyer JM; Rebika H; Pouliquen P; Catalina P; Dubray C; Beytout J
    Clin Microbiol Infect; 2007 Apr; 13(4):395-403. PubMed ID: 17359323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults.
    Valera R; García HM; Jidy MD; Mirabal M; Armesto MI; Fando R; García L; Fernández R; Año G; Cedré B; Ramírez M; Bravo L; Serrano T; Palma S; González D; Miralles F; Medina V; Nuñez F; Plasencia Y; Martínez JC; Mandarioti A; Lugones J; Rodríguez BL; Moreno A; González D; Baro M; Solis RL; Sierra G; Barbera R; Domínguez F; Gutiérrez C; Kouri G; Campa C; Menéndez J
    Vaccine; 2009 Nov; 27(47):6564-9. PubMed ID: 19720365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic vaccines for nicotine dependence.
    Maurer P; Bachmann MF
    Curr Opin Mol Ther; 2006 Feb; 8(1):11-6. PubMed ID: 16506520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
    Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
    Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expecting the antinicotine vaccine].
    Didilescu C
    Pneumologia; 2009; 58(3):177-8. PubMed ID: 19817315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.